<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871311</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0039</org_study_id>
    <nct_id>NCT01871311</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors</brief_title>
  <official_title>A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended Phase II dose of nilotinib when&#xD;
      used in combination with cetuximab in the treatment of patients with recurrent and/or&#xD;
      metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABL1 has been suggested to play a key role in the resistance mechanism to anti EGFR therapy&#xD;
      in cancer. Therefore, this study aims to evaluate the safety and possible effect of targeting&#xD;
      both EGFR using cetuximab along with ABL1 using nilotinib. Correlative studies assess the&#xD;
      changes in tumor proteome in response to therapy and magnitude of ADCC as a marker of&#xD;
      antibody activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary investigator left the institution.&#xD;
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>18 months</time_frame>
    <description>The dose at which &lt;/= 1 out of 6 subjects experiences a dose limiting toxicity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Nilotinib + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib + Cetuximab</intervention_name>
    <description>Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly&#xD;
Three dose levels for nilotinib:&#xD;
Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID&#xD;
Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity.</description>
    <arm_group_label>Nilotinib + Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma&#xD;
             of the head and neck&#xD;
&#xD;
          2. Previous therapy:&#xD;
&#xD;
               1. Patients must have progressed after standard therapy for metastatic/recurrent&#xD;
                  disease, including irinotecan and oxaliplatin-containing regimens for patients&#xD;
                  with CRC and platinum-containing regimens for patients with H&amp;NSCC.&#xD;
&#xD;
               2. Patients may have received cetuximab or panitumumab previously&#xD;
&#xD;
          3. Ability to swallow medication tablets by mouth (which may include taking nilotinib&#xD;
             mixed in apple sauce)&#xD;
&#xD;
          4. At least one measurable lesion by RECIST criteria&#xD;
&#xD;
          5. A tumor lesion that can be readily biopsied using a core needle via clinical exam or&#xD;
             image-guidance.&#xD;
&#xD;
          6. Over the age of 18 years and able to provide informed consent&#xD;
&#xD;
          7. Adequate kidney, liver, and bone marrow function as follows:&#xD;
&#xD;
               1. Hemoglobin &gt;/= 8.0 gm/dL&#xD;
&#xD;
               2. Absolute neutrophil count &gt;/= 1500&#xD;
&#xD;
               3. Platelet count &gt;/= 100,000&#xD;
&#xD;
               4. Creatinine within institutional normal limits or glomerular filtration rate &gt; 60&#xD;
&#xD;
               5. Total bilirubin f. AST and ALT&#xD;
&#xD;
          8. Life expectancy of greater than 3 months&#xD;
&#xD;
          9. ECOG performance status&#xD;
&#xD;
         10. Normal left ventricular ejection fraction, defined as EF &gt; 50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy or surgery within 4 weeks prior to treatment start&#xD;
&#xD;
          2. Radiation treatment within 3 weeks prior to treatment start&#xD;
&#xD;
          3. Prior therapy with nilotinib, ponatinib, dasatinib, or imatinib&#xD;
&#xD;
          4. Untreated brain metastases or neurologically unstable central nervous system&#xD;
             metastases; CNS metastases will be considered stable if there is no new nor enlarging&#xD;
             lesions for one month, and the patient remains off steroids and anti-epileptics for&#xD;
             the same time period&#xD;
&#xD;
          5. Any severe or uncontrolled medical condition or other condition that could affect&#xD;
             participation in this study, including: unstable angina, uncontrolled hypertension,&#xD;
             serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial&#xD;
             infarction&#xD;
&#xD;
          6. Diarrhea &gt; Grade 1 at baseline&#xD;
&#xD;
          7. Concomitant medication or herbal therapy known to inhibit CYP3A4&#xD;
&#xD;
          8. Gastrointestinal tract disease resulting in the inability to take oral medication or a&#xD;
             requirement for IV alimentation, prior surgical procedures affecting absorption, or&#xD;
             active peptic ulcer disease&#xD;
&#xD;
          9. Ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade &gt;/= 2&#xD;
&#xD;
         10. Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or&#xD;
             ventricular fibrillation &gt;/= 3 beats in a row)&#xD;
&#xD;
         11. Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
         12. QTc interval &gt; 500 msec&#xD;
&#xD;
         13. Female patients who are pregnant or breast feeding, or adults who are of reproductive&#xD;
             potential and are unwilling to refrain from conceiving a child during study treatment&#xD;
&#xD;
         14. Patients unwilling or unable to comply with the protocol, or provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann W Gramza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic Kras wildtype</keyword>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>cetuximab</keyword>
  <keyword>nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

